SCHEMBL6720449

SCHEMBL6720449

O=S(=O)(Nc1cccc(C2=NCCc3ccc(Cl)cc32)c1)c1ccc2ccccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.48
LMNA P02545 2/20 0.48
HTT P42858 2/20 0.48
MAPT P10636 1/20 0.48
HTR6 P50406 4/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PKM P14618 2/20 0.45
HTR1A P08908 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR7 P34969 1/20 0.45
DRD3 P35462 1/20 0.45
NLRP3 Q96P20 1/20 0.44
PKLR P30613 1/20 0.44
PLAU P00749 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GGPS1 O95749 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723046 0.91 ATM (0.48) LMNAMAPTHTR6MEN1KMT2A
SCHEMBL6720428 0.89 PFKFB3 (0.53) PFKFB3LMNAHTTMAPTHTR6
SCHEMBL6716742 0.89 PFKFB3 (0.48) PFKFB3LMNAHTTMAPTHTR6
SCHEMBL6714837 0.87 MEN1 (0.43) LMNAHTTMAPTHTR6MEN1
SCHEMBL6714986 0.86 LMNA (0.48) LMNAMAPTHTR6MEN1KMT2A
SCHEMBL6717849 0.86 PGR (0.47) LMNAMAPTHTR6PKMHTR2A
SCHEMBL6718056 0.84 ATM (0.47) LMNAMAPTMEN1KMT2APKM
SCHEMBL6715003 0.84 HSP90AA1 (0.46) HTR6MEN1KMT2ASMN1; SMN2FBP1
SCHEMBL6714772 0.84 CCR9 (0.48) LMNAHTTHTR6HTR2AHTR2C
SCHEMBL7214704 0.84 DRD2 (0.48) HTR6HTR2AHTR2CDRD3MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A PFKFB3 2298/4885LMNA 1790/4885HTT 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.